Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology

▴ Everest Medicines
Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study of etrasimod for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal.

HONG KONG, Oct 9, 2025 - (ACN Newswire) - Everest Medicines today announced that the results of its Asian multicenter Phase III ENLIGHT UC study (ES101002) of etrasimod (VELSIPITY(R)) for the treatment of subjects with moderately to severely active ulcerative colitis (UC) have been published in the prestigious international journal The Lancet Gastroenterology & Hepatology, marking the global recognition of this next-generation selective S1P receptor modulator’s efficacy in Asian patients.

The published results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind, placebo-controlled Phase III trial of etrasimod conducted across Asia. ENLIGHT is the largest completed Phase III trial to date in Asian patients with moderately to severely active UC, enrolling 340 eligible subjects who were randomized to receive once-daily etrasimod or placebo for 12 weeks of induction treatment. All patients had an inadequate response or intolerance to at least one conventional, biologic, or Janus kinase (JAK) inhibitor therapy.

The study results showed that, during both the 12-week induction phase and the 40-week maintenance phase, etrasimod demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints. The safety profile of etrasimod was consistent with previous studies, with no new safety signals observed.

Prof. Wu Kaichun at the First Affiliated Hospital of AFMU who is the principal investigator for etrasimod’s Asia clinical trial said: “As the largest Phase III trial of UC in Asia, the results fill the gap in clinical data on active UC in Asia. The results confirm that etrasimod shows good efficacy and safety in Asian patients including Chinese patients, with positive effects on improving clinical symptoms and promoting endoscopic improvement.”

“Publication of the ENLIGHT UC study in The Lancet Gastroenterology & Hepatology underscores etrasimod’s strong clinical value in the treatment of moderately to severely active UC and providing stronger clinical evidence to support patients across Asia.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.“The company initiated local production of etrasimod in March and remains committed to accelerating the regulatory approval process in Mainland China and other Asian markets, helping more patients achieve higher-quality, longer-lasting disease remission.”

VELSIPITY(R) has been approved in Singapore, Macao SAR, and Hong Kong SAR. Its NDA has also been accepted in South Korea and Taiwan, China. In December 2024, China’s National Medical Products Administration (NMPA) officially accepted the NDA for VELSIPITY(R), with approval expected in the first half of 2026. As Everest’s third commercialized product, VELSIPITY(R) has been approved by the Guangdong Provincial Medical Products Administration for adult patients with moderately to severely active UC, and is now available at medical institutions designated under the Connect Policy in the Greater Bay Area. The localized production project for VELSIPITY(R) was officially launched at the Jiashan manufacturing site in March 2025, providing strong support for its future commercialization.

As a core product of Everest Medicines, etrasimod is an innovative and advanced therapy that provides rapid onset of action, clinical remission and endoscopic improvement through an oral, once-daily regimen. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline as a first-line treatment for ulcerative colitis in December 2024, etrasimod was included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, strongly recommended for both induction and maintenance of remission in patients with moderately to severely active UC.

From the market perspective, the number of UC patients in Asia is rising rapidly, while treatment options remain relatively limited. In China alone, the UC patient population was estimated at approximately 800,000 in 2024 and is projected to reach 1.5 million by 2031. With its proven efficacy and safety, VELSIPITY(R) is expected to quickly enter and reshape the market landscape. To ensure accessibility and supply stability, Everest has launched a localized production project at its Jiashan manufacturing site, with an expected annual production capacity of up to 50 million tablets to enhance supply stability and cost efficiency.

Notably, in late August Everest launched a proactive build-up of its commercial team for etrasimod, with the team expected to expand significantly around the time of approval. This deployment will not only ensure the efficient commercialization of VELSIPITY(R) upon launch, but also lay a solid foundation for future inclusion in the National Reimbursement Drug List (NRDL) and large-scale uptake.

Industry observers widely expect VELSIPITY(R) to become Everest’s next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest’s revenue mix and growth trajectory are expected to strengthen further, providing greater visibility and confidence for long-term investors.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
AI-Enabled Endoscopy: Can It Detect More Than the Human Eye?November 20, 2026
Hospital-at-Home in India: Can Technology Deliver Safe Care?November 20, 2026
Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026